EBS Emergent BioSolutions Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1367644 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-17.7%
TTM net income YoY-443.5%
TTM EPS YoY-475.0%
Revenue 3-yr CAGR-16.2%
Net income 3-yr CAGR—
Margins
Gross margin48.4%
Operating margin-27.7%
Net margin-40.2%
FCF margin29.0%
EBITDA margin-18.4%
Returns
ROE-58.2%
ROA-21.2%
ROIC (approx.)-17.3%
Asset turnover0.53x
Leverage & solvency
Liabilities / assets68.5%
Debt / equity1.62x
Current ratio4.58x
Interest coverage-3.96x
Cash quality & payout
Operating cash flow / net income-0.77x
Accruals ratio-37.5%
Payout ratio—
Capex / revenue1.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $742.90M | $1.04B | $1.05B | $1.12B | $1.77B |
| Cost of revenue | $326.20M | $681.30M | $705.40M | $693.10M | $748.10M |
| Gross profit | $416.70M | $362.30M | $317.60M | $383.00M | $891.30M |
| R&D expense | $53.20M | $70.70M | $111.40M | $188.30M | $235.20M |
| SG&A expense | $186.10M | $308.00M | $368.40M | $339.50M | $348.70M |
| Operating income | $100.10M | -$108.70M | -$726.40M | -$170.00M | $341.40M |
| Interest expense | $59.30M | $71.00M | $87.90M | $37.30M | $34.50M |
| Pretax income | $82.80M | -$142.90M | -$731.20M | -$219.00M | $303.20M |
| Income tax | $30.20M | $47.70M | $29.30M | -$7.40M | $83.70M |
| Net income | $52.60M | -$190.60M | -$760.50M | -$211.60M | $219.50M |
| EBITDA | $195.90M | $100,000 | -$601.30M | -$26.70M | $465.20M |
| EPS (basic) | 0.98 | -3.60 | -14.85 | -4.22 | 4.10 |
| EPS (diluted) | 0.93 | -3.60 | -14.85 | -4.22 | 4.06 |
| Weighted avg. shares (diluted) | 56.70M | 53.00M | 51.20M | 50.10M | 54.10M |
| Balance sheet | |||||
| Cash & equivalents | $205.40M | $105.60M | $111.70M | $642.60M | $576.30M |
| Receivables | $84.20M | $154.50M | $191.00M | $159.20M | $278.90M |
| Inventory | $343.40M | $311.70M | $328.90M | $350.70M | $344.50M |
| Current assets | $662.50M | $598.70M | $679.50M | $1.21B | $1.27B |
| PP&E, net | $205.40M | $270.60M | $382.80M | $817.60M | $800.10M |
| Goodwill | $0 | $0 | $0 | $218.20M | $224.90M |
| Intangibles | $436.50M | $501.50M | $566.60M | $728.80M | $604.60M |
| Total assets | $1.32B | $1.39B | $1.82B | $3.17B | $2.96B |
| Current liabilities | $132.20M | $162.40M | $651.30M | $1.23B | $374.00M |
| Short-term debt | — | $0 | $413.70M | $957.30M | $31.60M |
| Long-term debt | $572.10M | $663.70M | $446.50M | $448.50M | $809.40M |
| Total debt | $572.10M | $663.70M | $860.20M | $1.41B | $841.00M |
| Total liabilities | $796.00M | $906.90M | $1.17B | $1.78B | $1.35B |
| Shareholders' equity | $522.60M | $482.80M | $649.30M | $1.39B | $1.61B |
| Net debt | $366.70M | $558.10M | $748.50M | $763.20M | $264.70M |
| Shares outstanding | 52.10M | 54.30M | 52.20M | 50.10M | 51.30M |
| Cash flow statement | |||||
| Operating cash flow | $170.60M | $58.70M | -$206.30M | -$34.10M | $320.20M |
| Capital expenditure | $13.80M | $22.90M | $51.60M | $115.80M | $224.10M |
| Free cash flow | $156.80M | $35.80M | -$257.90M | -$149.90M | $96.10M |
| Investing cash flow | $69.40M | $125.20M | $212.30M | -$381.30M | -$224.10M |
| Financing cash flow | -$136.60M | -$190.00M | -$535.70M | $481.20M | -$141.00M |
| Depreciation & amortization | $95.80M | $108.80M | $125.10M | $143.30M | $123.80M |
| Stock-based compensation | $16.20M | $18.00M | $23.10M | $45.10M | $42.40M |
| Share buybacks | $24.90M | $0 | $0 | $82.10M | $106.00M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.